National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

  • Inotuzumab ozogamicin (Besponsa®) - September 14, 2018

    The NCPE recommends that inotuzumab should be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Nivolumab (Opdivo®) for urothelial carcinoma - September 13, 2018

    The NCPE recommends that nivolumab (Opdivo®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Tolvaptan (Jinarc®) - September 13, 2018

    The NCPE recommends that tolvaptan not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.

  • Idebenone (Raxone®) - August 30, 2018

    The NCPE recommends that idebenone not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Ocrelizumab (Ocrevus®) for RMS - August 29, 2018

    The NCPE recommends that ocrelizumab (Ocrevus®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Ribociclib (Kisqali®) - August 13, 2018

    Following NCPE assessment of the company submission, the NCPE recommends that ribociclib (in combination with an aromatase inhibitor) for the treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic BC as initial endocrine-based therapy, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Cladribine (Mavenclad®) - July 20, 2018

    Following NCPE assessment of the company submission, cladribine (Mavenclad®) is considered cost-effective for the treatment of adult patients with highly active relapsing MS as defined by clinical or imaging features and therefore is recommended for reimbursement.

  • Cabozantinib (Cabometyx®) - July 4, 2018

    The NCPE recommends that cabozantinib (Cabometyx®) for the treatment of advanced or metastatic clear-cell RCC not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Sebelipase alfa (Kanuma®) - June 8, 2018

    The NCPE recommends for the infantile presentation, that sebelipase alfa (Kanuma®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. For the paediatric adult presentation, sebelipase alfa has not demonstrated robust evidence of additional clinical benefit and recommends that sebelipase alfa not be considered for reimbursement. These recommendations should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Pembrolizumab (Keytruda®) for NSCLC (second line) - May 29, 2018

    The NCPE recommends that pembrolizumab (Keytruda) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.